Analyst consensus rating
Filana Therapeutics Analyst Rating: Strong Buy
Direct answer
Filana Therapeutics's consensus rating is Strong Buy.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.50.
Forecast evidence checked November 18, 2026.
Get free Filana Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.48
- Average price target
- $6.50
- High price target
- $8.00
- Low price target
- $5.00
- Low target gap
- +939.7%
- Target upside
- +1,251.6%
- High target gap
- +1,563.5%
- Target range width
- 623.8%
- Consensus rating
- Strong Buy
- Analysts
- 2
- Evidence date
- November 18, 2026
- Valid through
- November 25, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Filana Therapeutics?
Filana Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $6.50.
How far are Filana Therapeutics's low and high targets from the recorded price?
The low target implies +939.7%, while the high target implies +1,563.5%.
How many analysts are included in Filana Therapeutics's consensus?
The verified consensus includes 2 analysts.
How is Filana Therapeutics's target upside or downside calculated?
The average target of $6.50 is divided by the recorded price of $0.48, then one is subtracted to produce +1,251.6%. This does not guarantee a future return.
When was Filana Therapeutics's analyst forecast verified?
The data was verified on 2026-11-18. The dataset is valid through 2026-11-25.